Chandra Pharma Key Ratios
BSE: 542934
₹50.40
₹0.50
(1.00%)
As on 27-Aug-2026IST
Market cap
₹38 Cr
Revenue (TTM)
₹116 Cr
P/E Ratio
12.5
P/B Ratio
1.2
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -- | -- | 30.93 | -0.96 | 10.46 |
| EBIT | -- | -- | 959.20 | -3.52 | -5.01 |
| Net Profit | -- | -- | 255.11 | 49.84 | 74.20 |
| EPS | -- | -- | 255.11 | 49.84 | 74.20 |
| Book Value | -- | -- | 11.43 | 7.46 | 6.05 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | Mar-26 | Mar-25 | Mar-24 |
| EBIT-Margin
| -0.49 | 0.80 | 2.37 | -0.36 | -3.47 |
| Net Margin
| 1.38 | 1.14 | 2.55 | 0.93 | 0.66 |
| Return on equity
| 6.10 | 5.00 | 9.76 | 2.96 | 5.58 |
| Return on Capital
| 8.96 | 8.60 | 12.24 | 6.54 | 8.09 |
| Return on Assets
| 1.95 | 1.66 | 3.12 | 0.84 | 1.89 |
| Debt to Equity (x)
| -- | -- | 0.50 | 0.71 | 0.58 |
Profitability
ROCE
12.24
Lower than Peers by 2.66
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Chandra Pharma
|
12.24
|
6.54
|
8.09
|
7.30
|
8.83
|
|
Peer Median
|
14.90
|
14.72
|
18.85
|
11.60
|
--
|
ROE
9.76
Lower than Peers by 3.01
Profit after tax / Average Net worth * 100
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Chandra Pharma
|
9.76
|
2.96
|
5.58
|
3.49
|
3.19
|
|
Peer Median
|
12.77
|
11.67
|
14.92
|
11.46
|
--
|
ROA
3.12
Lower than Peers by 3.97
Profit after tax / Average Total assets * 100
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Chandra Pharma
|
3.12
|
0.84
|
1.89
|
1.36
|
1.10
|
|
Peer Median
|
7.09
|
7.86
|
9.06
|
6.44
|
--
|
EBIT Margin
2.37
Lower than Peers by 11.70
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Chandra Pharma
|
2.37
|
-0.36
|
-3.47
|
2.56
|
2.88
|
|
Peer Median
|
14.07
|
15.03
|
14.71
|
12.37
|
--
|
Net Margin
2.55
Lower than Peers by 6.00
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Chandra Pharma
|
2.55
|
0.93
|
0.66
|
0.75
|
0.83
|
|
Peer Median
|
8.54
|
9.33
|
8.49
|
10.02
|
--
|
Cash Profit Margin
3.51
--
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Chandra Pharma
|
3.51
|
1.96
|
0.91
|
0.85
|
0.89
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Revenue Growth
30.93
Higher than Peers by 17.89
Year on year growth in net sales
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Chandra Pharma
|
30.93
|
-59.88
|
84.98
|
27.21
|
33.07
|
|
Peer Median
|
13.04
|
10.27
|
11.85
|
9.08
|
--
|
EBIT Growth
959.20
Higher than Peers by 942.03
Year on year growth in operating profit (EBIT)
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Chandra Pharma
|
959.20
|
95.83
|
-350.55
|
13.05
|
-23.82
|
|
Peer Median
|
17.18
|
24.15
|
28.00
|
-3.12
|
--
|
Net Profit Growth
255.11
Higher than Peers by 230.27
Year on year growth in profit after tax
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Chandra Pharma
|
255.11
|
-43.95
|
69.02
|
13.64
|
319.54
|
|
Peer Median
|
24.83
|
30.29
|
36.51
|
-0.85
|
--
|
EPS Growth
255.11
Higher than Peers by 237.30
Year on year growth in earnings per share
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Chandra Pharma
|
255.11
|
-43.95
|
69.02
|
13.65
|
319.51
|
|
Peer Median
|
17.80
|
24.50
|
--
|
-6.82
|
--
|
Book Value Growth
11.43
--
Year on year growth in book value per share
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Chandra Pharma
|
11.43
|
4.16
|
6.92
|
4.36
|
3.60
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
0.50
Higher than Peers by 0.30
Total debt / Net worth
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Chandra Pharma
|
0.50
|
0.71
|
0.58
|
0.71
|
0.83
|
|
Peer Median
|
0.21
|
0.23
|
0.20
|
0.15
|
--
|
Short term debt to equity ratio
0.40
--
(Short term borrowings / Net worth)
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Chandra Pharma
|
0.40
|
0.60
|
0.48
|
0.50
|
0.54
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
1.50
Lower than Peers by 0.33
Current Assets / Current Liabilities and Provisions
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Chandra Pharma
|
1.50
|
1.37
|
1.38
|
2.16
|
1.86
|
|
Peer Median
|
1.83
|
1.79
|
1.96
|
2.08
|
--
|
Quick Ratio
1.42
Higher than Peers by 0.22
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Chandra Pharma
|
1.42
|
1.36
|
1.26
|
1.08
|
0.96
|
|
Peer Median
|
1.20
|
1.47
|
1.44
|
1.58
|
--
|
Interest Coverage
3.05
Lower than Peers by 5.12
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Chandra Pharma
|
3.05
|
1.60
|
2.63
|
1.53
|
1.34
|
|
Peer Median
|
8.17
|
9.42
|
8.58
|
15.41
|
--
|
Operating Efficiency
Debtors to sales
46.97
Higher than Peers by 21.83
Debtors outstanding / Net Sales * 100
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Chandra Pharma
|
46.97
|
40.48
|
17.82
|
6.84
|
15.95
|
|
Peer Median
|
25.14
|
25.82
|
26.12
|
22.96
|
--
|
Asset Turnover
1.19
Higher than Peers by 0.46
Sales / Average Total Assets
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Chandra Pharma
|
1.19
|
0.87
|
2.73
|
1.80
|
1.30
|
|
Peer Median
|
0.73
|
0.75
|
0.77
|
0.65
|
--
|
Receivable days
142.15
--
Average Debtors / Sales * 365
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Chandra Pharma
|
142.15
|
154.94
|
39.27
|
35.37
|
59.02
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
8.42
--
Average Inventory / Sales * 365
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Chandra Pharma
|
8.42
|
19.25
|
31.12
|
96.43
|
134.43
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
79.66
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Chandra Pharma
|
79.66
|
55.25
|
14.33
|
9.89
|
34.83
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
70.91
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Chandra Pharma
|
70.91
|
118.94
|
56.06
|
121.91
|
158.62
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
7.55
Lower than Peers by 34.51
Current share price divided by earning per share in the last twelve months
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Chandra Pharma
|
7.55
|
46.03
|
46.84
|
80.83
|
107.78
|
|
Peer Median
|
42.06
|
39.70
|
33.48
|
37.74
|
--
|
Price / Book Value
0.70
Lower than Peers by 3.89
Current share price divided by book value per share in the latest financial year
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Chandra Pharma
|
0.70
|
1.34
|
2.53
|
2.76
|
3.38
|
|
Peer Median
|
4.59
|
3.72
|
4.21
|
3.22
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Chandra Pharma
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.10
|
0.16
|
0.21
|
0.57
|
--
|
EV/EBITDA
5.10
Lower than Peers by 24.86
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Chandra Pharma
|
5.10
|
14.94
|
20.10
|
24.69
|
23.18
|
|
Peer Median
|
29.97
|
30.23
|
29.90
|
28.81
|
--
|
Market Cap
23
Lower than Peers by 4,981
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Chandra Pharma
|
23
|
39
|
72
|
73
|
86
|
|
Peer Median
|
5,004
|
4,851
|
2,099
|
15,272
|
--
|
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
